Incidence of diarrhea in colon cancer patients receiving mFOLFOX-6 therapy Signs and Symptoms
Conditions
Interventions
Treatment Plan (Chemotherapy)
All patients will be treated with the standard mFOLFOX-6 consisting of 2-hour intravenous (IV) infusion of oxaliplatin (85 mg/m²) on day 1, and 2-hour IV drip infusion of
Sponsors
Taif University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients of both genders 2. Aged =18 years 3. Have histologically confirmed colon adenocarcinoma stage II, and III according to American Joint Committee on Cancer and the Union for International Cancer Control (AJCC-UICC); 7th Edition 4. Have adequate hematological parameters (evidenced by white blood cell count = 4000/µl and platelet count = 100,000/µl). 5. Have adequate renal (creatinine < 1.5 mg/dl) and hepatic functions (serum total bilirubin < 1.5 mg/dl).
Exclusion criteria
Exclusion criteria: 1. Patients with stage IV colon cancer. 2. Patients with second primary colon cancer. 3. Patients with colon cancer with any other co-morbidity.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| At baseline (prior to chemotherapy) and after two, four, and six cycles of treatment: 1. Treatment response to chemotherapy will be assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) 2. Diarrhea will be graded according to the National cancer institute. | — |
Secondary
| Measure | Time frame |
|---|---|
| Treatment-related toxicities will be estimated according to standard World Health Organization (WHO) criteria at the baseline and after two, four, and six cycles of treatment | — |
Countries
Egypt
Outcome results
None listed